Bausch + Lomb valued at $6.5 billion after stock ticks up in NYSE debut -Breaking
[ad_1]
© Reuters. The screen shows the ICE trading information at the New York Stock Exchange’s (NYSE) floor in New York City. This was March 21st, 2022. REUTERS/Brendan McDermidNiket Nishant
(Reuters) –Bausch + Lomb’s U.S. debut market debut was Friday. The eye-care firm’s shares opened almost 3% higher than the offer price, which was far below its target range.
This modest investor reception comes amid a bleak year in U.S. capital market markets. It also highlights the difficulties facing IPO-bound Reddit Inc (F:), and Mobileye, the autonomous car unit. Intel Corp (NASDAQ:).
In recent months, fear over Ukraine’s conflict and a more cautious outlook on Federal Reserve policy tightening has forced many businesses to delay or cancel plans to publicly trade in the United States.
Matt Kennedy, Senior Strategist at Renaissance Capital, stated that yesterday’s sale-off was a unique time to price an IPO.
Investors need to have a greater degree of security in this market. Following the dip the market took last week, most companies will be reevaluating their IPO plans.
On Thursday, major U.S. stock indices fell more than 3 percent due to concerns that the Fed’s most recent interest rate increase since 2000 will not suffice in taming inflation. The indexes also fell on Friday. [.N]
Bausch + Lomb stock closed at $18.50 compared to the IPO price $18, well below its target range of $21- $24.
The IPO brought in $630m for the seller shareholder. It was a unit from Bausch + Lomb’s parent Bausch Health Companies (NYSE 🙂 Inc.
This year, the offering was second in size after TPG Inc’s IPO. In January, it raised almost $1 billion.
Vaughan is an Ontario-based Bausch + Lomb. It was established in 1853 in New York as an optical goods store. They made lenses for the cameras that captured the first satellite image of the Moon.
The sunglasses were made for the American military during World War II. Bausch + Lomb also owned the Ray-Ban luxury eyewear brand, which it sold to Italy’s Luxottica Group.
It produces contact lenses, eye drops, and ophthalmic drugs. The portfolio includes over 400 products and is sold in almost 100 countries.
In 1958, the company was listed for the first time on NYSE. Warburg Pincus took over in 2007 and made it private.
Morgan Stanley The lead underwriters of the offering were Goldman Sachs (NYSE 🙂 and (NYSE :).
[ad_2]
